Chimerix

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chimerix transitions successfully, eyes oncology pipeline growth

Chimerix navigated a key transition in 2022, focusing on oncology pipeline
Financially, the company aims to fund operations into 2027
Promising clinical data on ONC201 and ONC206 highlight potential market opportunities

Chimerix reports operational and financial progress, poised for oncology growth

Chimerix demonstrated operational and financial progress in Q1 2023, with a strong focus on advancing its oncology pipeline and addressing analyst inquiries.
The company's innovative research capabilities, promising drug candidates, and solid financial position position it well for future growth and success.

Chimerix reports robust Q2 performance and strategic leadership recruitment

Chimerix's strong performance in global engagement and dose escalation studies positions them well for future growth in targeted oncology.
Maintaining financial discipline and leadership recruitment indicate a strategic approach to capital allocation and pipeline expansion.
Clear evaluation criteria and data sharing timelines will be crucial for addressing challenges and seizing opportunities in advancing their programs.

Chimerix (CMRX) advances oncology studies, poised for commercialization success

Chimerix (CMRX) showcased progress in ONC201 and ONC206 studies, with a focus on scientific validation and commercialization readiness.
Financially stable with a cash balance of $217 million, the company is well-positioned for future growth and operational sustainability.
Engagement with the medical community and strategic planning for market entry highlight Chimerix's commitment to innovation and patient care.

Chimerix reports disciplined finances, positive trial results, eyes global expansion

Chimerix showcased financial discipline amidst a net loss, while emphasizing positive Phase II results of ONC201. The company is focused on advancing the Phase III ACTION study with global enrollment and strategic management appointments. Challenges include timely execution of the study and managing enrollment trends, with opportunities in commercialization and partnerships.

Chimerix reports robust Q1 earnings, eyes global drug approvals

Chimerix's Q1 2024 earnings call highlighted strong financials, progress in key studies, and strategic growth initiatives. While facing challenges in enrollment, regulatory pathways, and commercialization, the company remains optimistic about its pipeline and financial discipline.

Chimerix advances key studies, maintains strong finances amid challenges

Chimerix (CMRX) demonstrated progress in key clinical studies and maintained a strong financial position in Q2 2024.
While facing challenges with increased R&D expenses and a net loss, the company is strategically investing in growth opportunities.
Opportunities lie in potential drug registrations, intensified dosing schedules, and investments in launch readiness for future success.
Overall, Chimerix remains focused on advancing its pipeline and financial strategy to drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021.

Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

Affimed

Epizyme

Seelos Therapeutics

Wave Life Sciences

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Small-Cap Biotech Stocks Trading Under $10 With Massive Upside Potential

DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright Global Life Sciences Conference made available on Tuesday, March 9, 2021 at 7:00 a.m. ET.

Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference

WESTON, Fla., Feb. 26, 2021 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung diseases and cancer, today announced that Chimerix, Inc. (NASDAQ:CMRX), worldwide licensee of...

Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial

Chimerix' (CMRX) CEO Mike Sherman on Q4 2020 Results - Earnings Call Transcript

Chimerix Inc (NASDAQ: CMRX) reports topline results from the first cohort (n=12) of its Phase 2/3 study evaluating DSTAT in hospitalized patients with Acute Lung Injury (ALI) and COVID-19 infection. The primary endpoint of the study is survival without the need for mechanical ventilation through day 28.

Chimerix's DSTAT Shows Promising Results In First Cohort Of COVID-19 Study

Billionaire investor Steven Cohen (Trades, Portfolio), who leads Point72 Asset Management, disclosed a 5.37% stake in Chimerix Inc. (NASDAQ:CMRX) earlier this week.

Steven Cohen Dives Into Chimerix

CMRX was an almost-dead company pursuing a dead-end indication. Its acquisition of Onconeutics has given it new life.

Chimerix: Recent Acquisition Gives This Laggard Antiviral Company A Fresh Start In Oncology

DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the closing of its previously announced underwritten public offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 1,764,750 shares of common stock. As a result, the Company issued a total of 13,529,750 shares in this offering at a price to the public of $8.50 per share. The gross proceeds to Chimerix from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were $115.0 million.

Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

DURHAM, N.C., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the pricing of its underwritten public offering of 11,765,000 shares of its common stock at a price to the public of $8.50 per share. All of the shares to be sold in the offering are being sold by Chimerix. The gross proceeds to Chimerix from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $100.0 million. In addition, Chimerix has granted the underwriters a 30-day option to purchase up to an additional 1,764,750 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 25, 2021.

Chimerix Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today that it intends to offer and sell, subject to market and other conditions, up to $75,000,000 of shares of its common stock in an underwritten public offering. In addition, Chimerix expects to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of shares of common stock. All of the shares to be sold in the offering are to be sold by Chimerix. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock

A new acquisition could be quite the shot in the arm for the company.

Why Chimerix Stock Skyrocketed on Friday

ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

Chimerix's (CMRX) NDA for brincidofovir as a medical countermeasure for smallpox has been accepted by the FDA.

Chimerx's (CMRX) NDA for Brincidofovir Accepted by FDA

FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021 FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021

Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox

Chimerix, Inc. (CMRX) CEO Michael Sherman on Q3 2020 Results - Earnings Call Transcript

DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Credit Suisse 29th Annual Healthcare Conference on Thursday, November 12, 2020 at 4:15 p.m. ET.

Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference

DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 5, 2020 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2020, and to provide a business overview.

Chimerix to Report Third Quarter 2020 Financial Results and Provide an Operational Update on November 5, 2020

DURHAM, N.C., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September:

Chimerix to Participate in Upcoming Investor Conferences

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q2 2020 Results - Earnings Call Transcript

Chimerix (CMRX) delivered earnings and revenue surprises of 11.11% and 19.83%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates

Shares of Chimerix (NASDAQ:CMRX) were flat in pre-market trading after the company reported Q2 results.

Recap: Chimerix Q2 Earnings

DURHAM, N.C., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2020, and to provide a business overview.

Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020

Former Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise Former Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise

Chimerix Appoints Allen Melemed, M.D. as Chief Medical Officer

Athersys

CytoSorbents

CytoDyn Inc.

Mesoblast

Below is a list of six companies with promising Covid-19 treatments in various stages of development, and the reasons why I have invested in them.

News for Chimerix Stock (CMRX)